A
phase 1 clinical study has
been held at the Institute of Aerospace Medicine in Bangalore India
between 2004 and 2006 on more than 100 terminal cancer patients. All
patients had undergone all possible conventional interventions such as
chemo, radiotherapy or surgery prior to RFQMR. Nothing more could be
offered and they were given
few months to live. Out of such patients :
- In
most of the patients the tumor progression was stopped or
reversed
- 78.3% felt
symptomatic relief (such as ease of pain, stop using pain killers,
no more weight loss etc)
- More than 58%
survived more than 1 year
- More than 33.3% went back to
normal lives and living disease free for 2
years
As
all these patients were expected to be dead by now, the outcomes of the
Cytotron
® therapy is outstanding. It is
believed that in patients who
are in a non-terminal situation (in better overall condition, with
stronger immune system and not subject to the toxic conventional
therapies with side effects) the efficacy of Cytotron
®
may be even more
pronounced.